Provided by Tiger Trade Technology Pte. Ltd.

CSTONE PHARMA-B

5.385
-0.065-1.19%
Volume:5.44M
Turnover:29.21M
Market Cap:8.59B
PE:-17.11
High:5.545
Open:5.500
Low:5.250
Close:5.450
52wk High:13.150
52wk Low:4.010
Shares:1.60B
HK Float Shares:1.60B
Volume Ratio:0.81
T/O Rate:0.34%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.315
ROE:-89.13%
ROA:-18.89%
PB:11.94
PE(LYR):-17.11
PS:27.33

Loading ...

CSTONE PHARMA-B Shares Surge Over 6% in Afternoon Trading on Analyst Upgrade

Stock News
·
Apr 10

CStone Pharma Reports Marginal Share Capital Movement in March; Issues 3,349 New Shares via Option Exercise

Bulletin Express
·
Apr 09

CStone Pharmaceuticals shifts to fully electronic distribution of corporate communications effective 2 April 2026

Bulletin Express
·
Apr 02

Adlai Nortye names Archie Tse president as Kaiyang Tang retires

Reuters
·
Apr 02

Gushengtang appoints Boyu Capital partner Cao Yanling as non-executive director

Reuters
·
Apr 01

A Look At CStone Pharmaceuticals (SEHK:2616) Valuation After Encouraging CS2009 Trial Results And Wider Losses

Simply Wall St.
·
Mar 31

Stock Track | CStone Pharma-B Soars 5.04% Intraday on Bullish Analyst Reports and Positive CS2009 Clinical Data

Stock Track
·
Mar 30

Two Major Foreign Institutions Bullish on CStone Pharma: Peak Target Price Set at HK$20, CS2009 Emerges as Key Catalyst

Stock News
·
Mar 30

CStone Pharmaceuticals' Loss Widens in 2025

MT Newswires Live
·
Mar 27

CStone Pharmaceuticals-B Surges Over 20% by Late Morning on Strong CS2009 Lung Cancer Efficacy Data

Deep News
·
Mar 27

CSTONE PHARMA-B (02616) Surges Over 20% on Strong CS2009 Lung Cancer Efficacy Data; First Phase III Global Trials Expected This Year

Stock News
·
Mar 27

Stock Track | CStone Pharma Soars 5.51% Intraday on Strong 2025 Results and Promising Pipeline Progress

Stock Track
·
Mar 27

Press Release: CStone Announces 2025 Annual Results: Accelerated Expansion of Global Commercial Footprint and Efficient Advancement of Innovation Pipeline 2.0

Dow Jones
·
Mar 26

CStone Pharmaceuticals - Loss for the Year Was RMB437.0 Million

THOMSON REUTERS
·
Mar 26

CStone Pharmaceuticals FY2025; revenue drops 33.8% to RMB 270 million due to lower licensing fees

Reuters
·
Mar 26

CStone reports 90% ORR in first-line NSCLC for trispecific antibody CS2009; Phase III global trials slated for 2026

Bulletin Express
·
Mar 26

CStone Pharmaceuticals-B Unveils Latest Clinical Progress and Phase I/II Key Data for Trispecific Antibody CS2009

Stock News
·
Mar 26

CStone Pharmaceuticals reports CS2009 Phase I safety; Grade ≥3 TRAEs rise to 23%

Reuters
·
Mar 26

CStone Pharmaceuticals reports CS2009 Phase I/II progress; ORR rises to 90% in first-line NSCLC with PD-L1 TPS≥50%

Reuters
·
Mar 26

CSTONE PHARMA-B Shares Extend Gains Following Top ESMO Guideline Recommendation for Core Product

Stock News
·
Mar 26